Industry Workshop presented by Cerus Corporation

Pathogen Reduced Blood Components – Current Experiences and Future Developments with the INTERCEPT® Blood System

Pathogen reduction has become the leading strategy to protect the US platelet supply, with over 1.4 million platelet components treated with the INTERCEPT Blood System per year.1,2
Hospital adoption of pathogen reduced blood components has expanded to include those for fibrinogen replacement. Dr. Jerry Squires of the Medical University of South Carolina (MUSC) and Cindy Ingold of Barnes-Jewish Hospital will discuss their experiences with INTERCEPT treated platelets and Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT Fibrinogen Complex (IFC).3 IFC, approved for the treatment and control of bleeding associated with fibrinogen deficiency with a 5-day post-thaw shelf life, has improved turnaround times for fibrinogen replacement at MUSC and Barnes-Jewish Hospital.
Finally, Dr. Edward Snyder of Yale New Haven Hospital will present recent findings from the ReCePI study, a Phase III randomized controlled trial evaluating the use of pathogen reduced red cell components in cardiovascular surgery patients.4

1. Estimate for platelet units treated with the INTERCEPT Blood System is based on the number of kits sold per year and total apheresis collections (Free RJ et al. Transfusion. 2023;1–11). 2. INTERCEPT Blood System for Platelets Package Insert (https://intercept-usa.com/resources/?dfg_filter=54%7C52). 3. INTERCEPT Blood System for Cryoprecipitation Package Insert (https://intercept-usa.com/resources/?dfg_filter=55%7C52). 4. The INTERCEPT Red Blood Cell system is in clinical development (ClinicalTrials.gov ID NCT03459287).

Speakers:
Jerry E. Squires, MD, PhD
Medical Director of Transfusion Service, Professor of Pathology and Transfusion Medicine
Medical University of South Carolina
Charlston, SC

Cindy L. Ingold, MLS (ASCP) SBB
Laboratory Manager, Transfusion Services
Barnes-Jewish Hospital
St. Louis, MO

Edward L. Snyder, MD, FACP
Medical Director of Transfusion Service
Professor of Laboratory Medicine and Pathology
Yale New Haven and Bridgeport Hospitals
New Haven, CT